A novel targeted approach to delineate a role for estrogen receptor-β in ameliorating murine mammary tumor-associated neuroinflammation.
Corena V GrantKathryn L G RussartLeah M PyterPublished in: Endocrine (2021)
Data presented here suggest that compensating for low circulating estrogen with ERβ brain activation is not sufficient to attenuate mammary tumor-induced neuroinflammation, and is therefore not a likely candidate for the treatment of behavioral symptoms in patients. The novel finding that mammary tumors alter estrogen signaling-related genes is a clinically relevant advancement to the understanding of how peripheral tumor biology modulates neurobiology. This is necessary to predict and prevent behavioral comorbidities (e.g., cognitive impairment) prevalent in cancer patients and survivors.
Keyphrases
- estrogen receptor
- cognitive impairment
- end stage renal disease
- traumatic brain injury
- lipopolysaccharide induced
- ejection fraction
- newly diagnosed
- cerebral ischemia
- chronic kidney disease
- lps induced
- young adults
- diabetic rats
- high glucose
- prognostic factors
- inflammatory response
- resting state
- drug delivery
- physical activity
- multiple sclerosis
- patient reported outcomes
- sleep quality
- combination therapy
- cancer therapy
- depressive symptoms
- subarachnoid hemorrhage
- breast cancer cells
- smoking cessation
- artificial intelligence
- blood brain barrier